Evaluation of tumor growth inhibition activity of a novel multi-TRK inhibitor ABP-1119 on pancreatic tumor xenograft model.

被引：0
|
作者：
Zhan, Zheng-Yun James [1 ]
Pan, Wanlong [1 ]
Zhang, Hao [1 ]
机构：
[1] AB Pharma Co Ltd, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16741
引用
收藏
页数：1
相关论文
共 37 条
  • [31] Discovery of LY2457546: a multi-targeted anti-angiogenic kinase inhibitor with a novel spectrum of activity and exquisite potency in the acute myelogenous leukemia-Flt-3-internal tandem duplication mutant human tumor xenograft model
    Burkholder, Timothy P.
    Clayton, Joshua R.
    Rempala, Mark E.
    Henry, James R.
    Knobeloch, John M.
    Mendel, David
    McLean, Johnathan A.
    Hao, Yan
    Barda, David A.
    Considine, Eileen L.
    Uhlik, Mark T.
    Chen, Yuefeng
    Ma, Liandong
    Bloem, Laura J.
    Akunda, Jacqueline K.
    McCann, Denis J.
    Sanchez-Felix, Manuel
    Clawson, David K.
    Lahn, Michael M.
    Starling, James J.
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (03) : 936 - 949
  • [32] Erratum to: Discovery of LY2457546: a multi-targeted anti-angiogenic kinase inhibitor with a novel spectrum of activity and exquisite potency in the acute myelogenous leukemia-Flt-3-internal tandem duplication mutant human tumor xenograft model
    Timothy P. Burkholder
    Joshua R. Clayton
    Mark E. Rempala
    James R. Henry
    John M. Knobeloch
    David Mendel
    Johnathan A. McLean
    Yan Hao
    David A. Barda
    Eileen L. Considine
    Mark T. Uhlik
    Yuefeng Chen
    Liandong Ma
    Laura J. Bloem
    Jacqueline K. Akunda
    Denis J. McCann
    Manuel Sanchez-Felix
    David K. Clawson
    Michael M. Lahn
    James J. Starling
    Investigational New Drugs, 2012, 30 (3) : 1270 - 1271
  • [33] Design and Development of a Novel Orally-Active, PI3K-p110Beta/Delta Inhibitor with Combined Tumor Immunotherapeutic, Growth Inhibition and Anti-Metastatic Activity
    Shuttleworth, Stephen Joseph
    BLOOD, 2015, 126 (23)
  • [34] Inhibition of tumor growth and post-treatment regrowth by SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, in combination with standard of care in pancreatic cancer models
    Bossard, Carine
    Astsaturov, Igor
    Cruz, Nathalia
    Eastman, Brian
    Mak, Chi-Ching
    Sunil, K. C.
    Tam, Betty
    Bucci, Gail
    Stewart, Josh
    Phalen, Timothy
    Cha, Steven
    CANCER RESEARCH, 2019, 79 (24)
  • [35] Inhibition of STAT3/5 pathway by multi-kinase inhibitor IQDMA reduces tumor growth and outperforms conventional phototherapeutic treatment regime in cutaneous T cell lymphoma murine model
    Dey, S.
    Wolf, P.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (11) : S373 - S373
  • [36] Monitoring Therapy with MEK Inhibitor U0126 in a Novel Wilms Tumor Model in Wt1 Knockout Igf2 Transgenic Mice Using 18F-FDG PET with Dual-Contrast Enhanced CT and MRI: Early Metabolic Response Without Inhibition of Tumor Growth
    Flores, Leo G., II
    Yeh, Hsin-Hsien
    Soghomonyan, Suren
    Young, Daniel
    Bankson, James
    Hu, Qianghua
    Alauddin, Mian
    Huff, Vicki
    Gelovani, Juri G.
    MOLECULAR IMAGING AND BIOLOGY, 2013, 15 (02) : 175 - 185
  • [37] Monitoring Therapy with MEK Inhibitor U0126 in a Novel Wilms Tumor Model in Wt1 Knockout Igf2 Transgenic Mice Using 18F-FDG PET with Dual-Contrast Enhanced CT and MRI: Early Metabolic Response Without Inhibition of Tumor Growth
    Leo G. Flores
    Hsin-Hsien Yeh
    Suren Soghomonyan
    Daniel Young
    James Bankson
    Qianghua Hu
    Mian Alauddin
    Vicki Huff
    Juri G. Gelovani
    Molecular Imaging and Biology, 2013, 15 : 175 - 185
1234